T1	Participants 29 46	multiple myeloma:
T2	Participants 140 230	patients entered on the Eastern Cooperative Oncology Group phase III E9486 clinical trial.
T3	Participants 495 511	myeloma patients
T4	Participants 628 784	CD19+ B cells by flow cytometry in previously untreated newly diagnosed myeloma patients in Eastern Cooperative Oncology Group (ECOG) phase III trial E9486.
T5	Participants 785 955	There were 628 patients who were eligible for the clinical protocol E9486, but of these 521 were also entered on the companion laboratory study (E9487) and had CD19 data.
T6	Participants 2851 2859	patients
T7	Participants 2921 2930	patients.
